Current advance of nanotechnology in diagnosis and treatment for malignant tumors

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: Aug. 12, 2024

Cancer remains a significant risk to human health. Nanomedicine is new multidisciplinary field that garnering lot of interest and investigation. shows great potential for cancer diagnosis treatment. Specifically engineered nanoparticles can be employed as contrast agents in diagnostics enable high sensitivity high-resolution tumor detection by imaging examinations. Novel approaches labeling are also made possible the use nanoprobes nanobiosensors. The achievement targeted medication delivery therapy accomplished through rational design manufacture nanodrug carriers. Nanoparticles have capability effectively transport medications or gene fragments tissues via passive active targeting processes, thus enhancing treatment outcomes while minimizing harm healthy tissues. Simultaneously, context radiation sensitization photothermal enhance therapeutic efficacy malignant tumors. This review presents literature overview summary how nanotechnology used According oncological diseases originating from different systems body combining pathophysiological features cancers at sites, we most recent developments applications. Finally, briefly discuss prospects challenges cancer.

Language: Английский

---

Osteosarcoma-Targeting PtIV Prodrug Amphiphile for Enhanced Chemo-Immunotherapy via Ca2+ trapping

Acta Biomaterialia, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 1, 2024

Language: Английский

---

Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy

Cancer Cell, Journal Year: 2023, Volume and Issue: 42(1), P. 35 - 51.e8

Published: Dec. 21, 2023

Language: Английский

---

Clinical Chemotherapeutic Agent Coordinated Copper‐Based Nanoadjuvants for Efficiently Sensitizing Cancer Chemo‐Immunotherapy by Cuproptosis‐Mediated Mitochondrial Metabolic Reprogramming

Advanced Functional Materials, Journal Year: 2023, Volume and Issue: 33(51)

Published: Aug. 17, 2023

Abstract Chemo‐immunotherapy has shown great success in boosting systemic anti‐tumor effects the clinic. However, cancer cells can escape maximum impact of chemotherapy through intracellular symbiotic bacteria and abnormally activated macropinocytosis, while immune evasion is largely facilitated by programmed cell death 1 ligand (PD‐L1) protein tumor‐secreted exosomes. To efficiently sensitize chemo‐immunotherapy, clinical mitoxantrone (MTO) therefore rationally coordinated with Cu 2+ to develop nanoscale metal‐organic frameworks (MTO‐Cu), then loaded macropinocytosis exosome secretion inhibitor amiloride (AMI) modified targeted chondroitin sulfate (CS) form CS/MTO‐Cu@AMI nanoadjuvant. Notably, effectively triggers cuproptosis‐induced mitochondrial dysfunction, which activates AMPK pathway‐mediated PD‐L1 degradation, deprives energy supply for release, amplifies oxidative stress deactivating bacteria, thus sensitizing chemo‐immunotherapy. Meanwhile, AMI suppresses act synergistically ‐caused chemo‐immunotherapy potentiation. Moreover, damaged dsDNA during treatment cGAS‐STING pathway, further evoking immunity. Additionally, attached CS endows specific tumor targeting hyaluronidase‐responsive charge reversal property, MTO‐Cu this nanoadjuvant pH/GSH dual‐responsive release behavior. Therefore, sensitizes antitumor immunity vitro vivo, providing an innovative solution potentiate

Language: Английский

---

Alendronate Triggered Dual‐Cascade Targeting Prodrug Nanoparticles for Enhanced Tumor Penetration and STING Activation of Osteosarcoma

Advanced Functional Materials, Journal Year: 2023, Volume and Issue: 33(49)

Published: Sept. 3, 2023

Abstract The complex physiological environment in bone tissue poses a challenge to the efficient delivery of chemotherapeutic agents for osteosarcoma (OS) treatment; hence, an drug system designed OS is highly desired. Herein, alendronate (Ale)‐based cationic platinum prodrug nanoparticles (Ale NP) are developed, which exhibit cascade responsiveness tumor microenvironment. With Ale triggered targeting and charge reversal effects, NP demonstrates superior capacity achieving deep penetration into dense tissues. Furthermore, can induce dendritic cell (DC) maturation via activation cyclic GMP‐AMP synthase‐stimulator interferon genes (cGAS‐STING) pathway using drugs. potent phenanthridine (Pt(II)) be released presence overexpressed glutathione (GSH) cells, thereby dual‐targeted drugs OS. Notably, not only effectively eliminates internal region but also acts as STING agonist reverse suppressive microenvironment Overall, Ale‐triggered dual‐cascade significantly improve OS, hence paving promising avenue clinical treatment

Language: Английский

---

Synergistic Chemoimmunotherapy Augmentation via Sequential Nanocomposite Hydrogel‐Mediated Reprogramming of Cancer‐Associated Fibroblasts in Osteosarcoma

Advanced Materials, Journal Year: 2023, Volume and Issue: 36(15)

Published: Dec. 19, 2023

In osteosarcoma, immunotherapy often faces hurdles posed by cancer-associated fibroblasts (CAFs) that secrete dense extracellular matrix components and cytokines. Directly removing CAFs may prove ineffective even promote tumor metastasis. To address this challenge, a sequential nanocomposite hydrogel reshapes CAF behavior is developed, enhancing tumor-infiltrating T-cells in osteosarcoma. The approach utilizes an injectable blend of carboxymethyl chitosan tetrabasic polyethylene glycol, forming for controlled release potent suppressor (Nox4 inhibitor, Nox4i) liposomal Doxorubicin (L-Dox) to induce immunogenic cell death (ICD) upon situ administration. Nox4i effectively counters activation, overcoming T-cell exclusion mechanisms, followed programmed L-Dox ICD induction stroma-rich osteosarcoma models. Combining the co-delivery gel with αPD-1 checkpoint inhibitor further enhances its effectiveness orthotopic model. Immunophenotyping data underscore significant boost infiltration favorable anti-tumor immunity at whole-animal level.

Language: Английский

---

Advancements in Photothermal Therapy Using Near-Infrared Light for Bone Tumors

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(8), P. 4139 - 4139

Published: April 9, 2024

Bone tumors, particularly osteosarcoma, are prevalent among children and adolescents. This ailment has emerged as the second most frequent cause of cancer-related mortality in Conventional treatment methods comprise extensive surgical resection, radiotherapy, chemotherapy. Consequently, management bone tumors regeneration poses significant clinical challenges. Photothermal tumor therapy attracted considerable attention owing to its minimal invasiveness high selectivity. However, key challenges have limited widespread use. Enhancing specificity photosensitizers through targeting or localized activation holds potential for better outcomes with fewer adverse effects. Combinations chemotherapies immunotherapies also present avenues improvement. In this review, we provide an overview recent strategies aimed at overcoming limitations photothermal (PTT), along current research directions context including (1) target strategies, (2) combined multiple therapies (immunotherapies, chemotherapies, chemodynamic therapies, magnetic, photodynamic therapies), (3) bifunctional scaffolds regeneration. We delve into pros cons these combination explore focal points. Lastly, address prospects therapy.

Language: Английский

---

Nanoparticles and bone microenvironment: a comprehensive review for malignant bone tumor diagnosis and treatment

Molecular Cancer, Journal Year: 2024, Volume and Issue: 23(1)

Published: Nov. 1, 2024

Malignant bone tumors, which are difficult to treat with current clinical strategies, originate from tissues and can be classified into primary secondary types. Due the specificity of microenvironment, results traditional means treating tumors often unsatisfactory, so there is an urgent need develop new treatments for malignant tumors. Recently, nanoparticle-based approaches have shown great potential in diagnosis treatment. Nanoparticles (NPs) gained significant attention due their versatility, making them highly suitable applications tissue engineering, advanced imaging techniques, targeted drug delivery. For diagnosis, NPs enhance contrast sensitivity by integrating targeting ligands, significantly improve specific recognition localization tumor cells early detection. treatment, enable delivery, increasing accumulation at sites while reducing systemic toxicity. In conclusion, understanding microenvironment using unique properties holds promise improving disease management, enhancing treatment outcomes, ultimately quality life patients Further research development will undoubtedly contribute advancement personalized medicine field oncology.

Language: Английский

---

PRKDC Induces Chemoresistance in Osteosarcoma by Recruiting GDE2 to Stabilize GNAS and Activate AKT

Cancer Research, Journal Year: 2024, Volume and Issue: 84(17), P. 2873 - 2887

Published: June 20, 2024

Abstract Chemoresistance is one of the major causes poor prognosis in osteosarcoma. Alternative therapeutic strategies for osteosarcoma are limited, indicating that increasing sensitivity to currently used chemotherapies could be an effective approach improve patient outcomes. Using a kinome-wide CRISPR screen, we identified PRKDC as critical determinant doxorubicin (DOX) The analysis clinical samples demonstrated was hyperactivated osteosarcoma, and functional experiments showed loss significantly increased DOX. Mechanistically, recruited bound GDE2 enhance stability protein GNAS. elevated GNAS levels subsequently activated AKT phosphorylation conferred resistance inhibitor AZD7648 DOX synergized strongly suppressed growth mouse xenograft models human organoids. In conclusion, PRKDC-GDE2-GNAS-AKT regulatory axis suppresses comprises targetable candidates improving efficacy chemotherapy Significance: Targeting activation increases which provides strategy overcoming chemoresistance.

Language: Английский

---

Engineering small-molecule and protein drugs for targeting bone tumors

Molecular Therapy, Journal Year: 2024, Volume and Issue: 32(5), P. 1219 - 1237

Published: March 6, 2024

Language: Английский

---